Navigation Links
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Date:4/25/2008

ng Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, which is on file with the SEC. Copies of this and other documents are available from the Company.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.

GENZYME SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including without limitation, statements concerning mipomersen's benefits for patients with high cholesterol, the development plan for mipomersen and FDA's requirements for its approval. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the timing of further discussions with FDA regarding the approval of mipomersen; the timing and content of submissions to and decisions made by the FDA relating to mipomersen; further analysis of clinical trial data; the results of other studies; the actual efficacy and safety of mipomersen; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

CONFERENCE CALL INFORMATION

At 8:00 a.m. Eastern Time Friday, April 25, Isis will conduct a live webcast conference call to discuss the mipomersen regulatory update. Interested parties may access the webcast at
'/>"/>

SOURCE Genzyme Corp. and Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... sex for one year will be allowed to donate blood in ... a 31-year ban on donations from men who have sex with ... intention to release a new draft guidance in early 2015 that ... The FDA is changing its policy based on data from ...
(Date:12/24/2014)... News) -- A new, injectable weight-loss drug has been ... The agency on Tuesday approved Saxenda (liraglutide) for adults ... and have at least one weight-related health condition, such ... cholesterol. Patients taking the drug, made by Novo ... regularly, the FDA noted. "Obesity is a public ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... Teens are more likely to start smoking or drinking ... disorder (ADHD) or conduct disorder, new research suggests. ... about the risk of substance use as [these] children ... director at Cincinnati Pediatric Research Group, which is part ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Gluten, a ... on those who have an intolerance to gluten, causing ... gas, bloating, migraine headaches, joint pain and fatigue. For ... diet plans that deliver safe and fast weight ... that trigger a gluten allergy reaction. These gluten free ...
(Date:12/24/2014)... 24, 2014 Dr. Svetlana Gomer, MGS ... the nation gathered with US Marines on November 14, ... funds for the Toys for Tots Literacy Program. ... of new books and audio books for the Toys ... children this Christmas. It represents another major strike in ...
Breaking Medicine News(10 mins):Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... The Johns Hopkins Bloomberg School of Public Health has awarded ... efforts to reduce polio globally as well as his work ... Democratic Republic of Congo. Mutombo will be presented with the ... Health in Baltimore, Md., on April 13. "Mr. Mutombo ...
... News) -- In most people, plaque formation in arteries occurs ... according to a new study. Researchers at the Karolinska ... surgery to remove plaque buildup in arteries in their neck. ... than the patients, who were on average 68 years old ...
... available in Spanish and French . ... a conflict arises within the couple. Conversely, it is men ... cause conflicts more frequently. This is the conclusion described ... prepared by professors from the Department of Social Psychology ...
... pregnant women, high induction and first-cesarean delivery rates do not ... published in the April issue of The Journal of ... of intervention at delivery whether high, low, or in ... new babies brings into question the skyrocketing number of both ...
... IL (April 13, 2011 ) This week at ... about dietary cholesterol intake and cardiovascular disease risk were ... variety of poster presentations. Experts from leading institutions discussed ... its association with heart disease risk, dispelling some commonly ...
... Children were the victims in more than half of the ... between 1997 and 2009, according to a new study by ... to prevent injury from the pressurized and often harsh chemical ... 0 to 4, were the most likely to be hurt ...
Cached Medicine News:Health News:Artery Plaque Forms in Short Time Span, Scientists Say 2Health News:Women have more intense emotions than men when conflict arises within the couple 2Health News:More interventions at delivery not linked to healthier newborns 2Health News:More interventions at delivery not linked to healthier newborns 3Health News:Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk 2Health News:Children victims of most eye injuries from aerosols 2
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... a first-in-human Phase 1 clinical trial of APD597, a ... the glucose-dependent insulinotropic receptor (GDIR) for the treatment of ... Arena and has the potential to stimulate insulin release ...
... Corporation of North,America today announced that the U.S. ... disodium) Injection, an intravenous,sedative-hypnotic agent for monitored anesthesia ... therapeutic procedures. , ... LUSEDRA be used only by persons,trained in the ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 3Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals 4FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 2FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 3FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: